Peter Casasanto

Peter Casasanto's work experience includes holding the position of Chief BioPharma Officer at SOPHiA GENETICS since 2022, where they focus on AI-enabled data-driven insights to drive biomarker discovery and improve clinical trial performance. Prior to that, they were the Vice President of New Commercialization Initiatives at CellCarta from 2021 to 2022. From 2019 to 2021, they worked at Tempus Labs, Inc., first as the Vice President of Corporate Development, Tempus ALPHA, and then as the Vice President of Life Sciences, where they leveraged machine learning/AI to analyze clinical and molecular data for precision medicine. Peter also has experience at NeoGenomics Laboratories as the Executive Director of Corporate Development & Strategy Head, Pharma Services from 2016 to 2019. Before that, they held roles at LabCorp Clinical Trials as the Senior Director of Business Development-Biomarkers & CDx from 2013 to 2016 and as the Director of Business Development-Biomarkers & CDx from 2013 to 2014. Prior to that, they worked at PPD as the Associate Director of Vaccines from 2009 to 2013, and at Merck as a Research Immunologist in the Program Management Group from 2005 to 2008. Peter started their career as an Associate Scientist at Thomas Jefferson University from 2003 to 2005.

Peter Casasanto completed their education at various institutions throughout the years. From 1997 to 2002, they attended the University of Maryland and obtained a Bachelor of Science degree in Molecular Biology and Genetics. Following this, from 2003 to 2005, they pursued a Master of Science degree in Biomedical Chemistry at Jefferson Health. Finally, from 2005 to 2008, Peter attended Drexel University's LeBow College of Business, where they earned an MBA degree specializing in Pharmaceutical Management.